Omega Therapeutics — Technical Presentation (September 2023)
23 slides from Omega Therapeutics's technical presentation, Sep 26, 2023
Slide 1: MYCHELANGELO I: Preliminary Phase 1 Clinical Update
September 26, 2023 MYCHELANGELO™ I: Preliminary Phase 1 Clinical Update
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-look
Slide 3: Today's Agenda
Today’s Agenda Welcome and Introductory Remarks Mahesh Karande, President and Chief Executive Officer Review of Preliminary Phase 1 Clinical Data from Ongoing MYCHELANGELO™ I Trial Thomas McCauley, Ph.D., Chief Scientific Officer Guest Speaker Gerard Evan, Ph.D., Principal Group Leader of the Franci
Slide 4: Introduction
Introduction Mahesh Karande President and Chief Executive Officer
Slide 5: Pioneering A New Era of Therapeutic Development
Pioneering A New Era of Therapeutic Development Unlocks potential of MYC, a historically ‘undruggable’ target Establishes clinical proof-of-platform; potential applicability across broad range of diseases Supports potential of epigenomic controllers as a new class of programmable mRNA medicines Deli
Slide 6: Epigenomic controllers solve multiple challenges in drug development
Existing modalities have limitations Restricted to druggable target structures or can only address narrow therapeutic areas Wide opportunity space in drug development remains Epigenomic controllers solve multiple challenges in drug development Independent of structure, chemistry or location of targe
Slide 7: OMEGA Platform Engineers Programmable mRNA Therapeutics
OMEGA Platform Engineers Programmable mRNA Therapeutics to Control Gene Expression Through Epigenetics Epigenomic Controller Epigenomic Controllers Enhancer EpiZip: HEP.20.qX.Y.Z.624 Promoter EpiZip: HEP.20.qX.Y.Z.623 Gene DNA / Insulated Genomic Domain (IGD) Bind to EpiZips (proprietary library of
Slide 8: Pipeline by target gene and indication
Target Gene(s) Indication EC Discovery Preclinical Clinical Phase 3 Phase 1 Phase 2 Phase 3 Oncology MYC Hepatocellular carcinoma OTX-2002* MYC Non-small cell lung cancer OTX-2101 Undisclosed Small cell lung cancer Multigenic Diseases CXCL 1-8 Potential franchise of programs** Undisclosed Idiopathic
Slide 9: MYC: The Holy Grail of Master Oncogenes
MYC: The Holy Grail of Master Oncogenes Primary driver of cancer growth and immune evasion in more than 50% of human cancers Strongly correlated with metastases and poor patient prognosis Historically ‘undruggable’ due to its disordered protein structure and autoregulation Potential solution: Contro
Slide 10: OTX-2002 Mechanism of Action
Site-specific target engagement Site-specific epigenetic state change (in vitro) OTX-2002 Mechanism of Action Preclinical Data Confirms Proof-of-Concept Through Epigenetic Modulation of MYC Control EC Treatment Genomic coordinates In vivo efficacy OTX-2002 treated Negative control Biomarker changes
Slide 11: Early Clinical Data Demonstrate Promising Potential of OTX-2002
Highly-specific binding at target genomic loci Intended epigenetic state change with on-target increase in methylation signature Rapid, robust and durable downregulation of MYC expression Encouraging safety and consistent PK profile Early Clinical Data Demonstrate Promising Potential of OTX-2002 Fir
Slide 12: MYCHELANGELO I Preliminary Data Overview
MYCHELANGELO™ I Preliminary Data Overview Thomas McCauley, Ph.D. Chief Scientific Officer
Slide 13: MYCHELANGELO I Phase 1/2 trial design
* Patients with HCC who progressed, relapsed, refractory or intolerant of >1 prior systemic therapy and without available subsequent SOC ** Tyrosine kinase inhibitors, and checkpoint inhibitors including anti-PD-1 and anti-PD-L1 monoclonal antibodies. Dose of SOC in accordance with approved dose in
Slide 14: Encouraging Emerging Safety Profile for OTX-2002
Encouraging Emerging Safety Profile for OTX-2002* Phase 1 Study Enrolled Difficult-to-Treat, Heavily Pretreated Population Dose Level Demographics Cancer Type at Initial Diagnosis # Prior Lines of Therapy Dose Level 1 0.02 mg/kg 78 / F / White Soft Tissue Sarcoma (Oct 2015) 3+ 51 / M / Asian HCC (Fe
Slide 15: Predictable Pharmacokinetics with Rapid Clearance
LNP Epigenomic Controller mRNA Predictable Pharmacokinetics with Rapid Clearance of Drug Product Observed Clinical Pharmacokinetics and Lack of Immunogenicity Directly Translate from Preclinical Experience OTX-2002 was cleared rapidly from systemic circulation No accumulation observed with repeat do
Slide 16: Highly-Specific Target Engagement and Epigenetic State Change
Highly-Specific Target Engagement and Intended Epigenetic State Change at Target Genomic Loci within MYC IGD Observed Pre-Dose OTX-2002 Dose Day 3 Day 8 Day 15 Dose Level 2 Methylation score (log) Dose Level 1 Methylation score (log) Target EpiZip Methylation score (log) Genomic Coordinates Green sh
Slide 17: Rapid, Robust & Durable Downregulation of MYC mRNA Expression
7 Rapid, Robust & Durable Downregulation of MYC mRNA Expression Observed Clinical MYC downregulation consistent with levels that led to robust anti-tumor efficacy in preclinical settings Dose Level 1 Dose Level 2 OTX-2002 Dose 1 MYC mRNA expression (Relative to Pre-Dose) Days 0 14 0.0 0.5 1.0 1.5 Ta
Slide 18: Key Takeaways and Next Steps
Preliminary Data Show Promising Potential of OTX-2002 and MYC Modulation First known clinical observation of pre-transcriptional control of gene expression using a programmable mRNA development candidate OTX-2002 directly targeted and therapeutically controlled historically ‘undruggable’ MYC in 8/8
Slide 19: Guest Speaker Gerard Evan, Ph.D.
Guest Speaker Gerard Evan, Ph.D. Principal Group Leader of the Francis Crick Institute in London; Professor of Cancer Biology at Kings College London
Slide 20: Closing Remarks
Closing Remarks Mahesh Karande President and Chief Executive Officer
Slide 21: Pioneering A New Era of Therapeutic Development
Pioneering A New Era of Therapeutic Development Unlocks potential of MYC, a historically ‘undruggable’ target Establishes clinical proof-of-platform; potential applicability across broad range of diseases Supports potential of epigenomic controllers as a new class of programmable mRNA medicines Deli
Slide 22: Q&A
Q&A Mahesh Karande President and Chief Executive Officer Thomas McCauley, Ph.D. Chief Scientific Officer
Slide 23: Thank You
) OMEGA Thank You
Omega Therapeutics — Technical Presentation (September 2023) on 6ix